173. Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL 2002 Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21:6255-63 174. Blackwell K, Kaplan EH, Franco SX, Marcom PK, Maleski JE, Sorensen MJ, Berger MS 2004 A phase II, open label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. Proceeding of the American Society of Clinical Oncology. 22:3006 175. Burris HA, 3rd, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch KM, Stead A, Mangum S, Spector NL 2005 Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23:5305-13 176. Marcom PK, Isaacs C, Harris L, Wong ZW, Kommarreddy A, Novielli N, Mann G, Tao Y, Ellis MJ 2006 The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of H<strong>ER</strong>2 positive and <strong>ER</strong> positive advanced breast cancers. Breast Cancer Res Treat 102(1):43-9 177. Mackey JR, Kaufman B, Clemens M, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Jones A Trastuzumab prolongs progression-free survival in hormone-dependent and H<strong>ER</strong>2-positive metastatic breast cancer. San 68
Antonio Breast Cancer Symposium (abstract 3). Breast Cancer Res and Treat 2006; 100 Suppl 1: S5, San Antonio, TX, 2006 178. Smith IE, Walsh G, Skene A, Llombart A, Ignacio Mayordomo J, Detre S, Salter J, Clark E, Magill P, Dowsett M 2006 Neoadjuvant Anastrozole Alone or With Gefitinib in Early Breast Cancer: A Phase II Placebo-Controlled Trial (Study 223) With Biological and Clinical Outcomes. J Clin Oncol Proceedings of the 2006 ASCO Annual Meeting; Part I (24) Suppl 18S:515 69
- Page 1 and 2:
Endocrine Reviews. First published
- Page 3 and 4:
Introduction Breast cancer evolutio
- Page 5 and 6:
endocrine therapy, might lead to th
- Page 7 and 8:
(also known as estrogen response el
- Page 9 and 10:
weaken the inhibitory effects of va
- Page 11 and 12:
that it is the E domain at the C-te
- Page 13 and 14:
independent or tamoxifen-mediated a
- Page 15 and 16:
(Iressa), which can block signaling
- Page 17 and 18: that HER2-positive breast cancer is
- Page 19 and 20: cases that received letrozole had a
- Page 21 and 22: preclinical model (102). Furthermor
- Page 23 and 24: suppressed/reduced PgR levels may d
- Page 25 and 26: PgR-negative tumors have more aggre
- Page 27 and 28: consequence of reversing ER-induced
- Page 29 and 30: gefitinib combined with estrogen de
- Page 31 and 32: performed in one of these trials, c
- Page 33 and 34: advanced breast cancer have recentl
- Page 35 and 36: act alone to stimulate tumor growth
- Page 37 and 38: Table 2. Selected recent ongoing an
- Page 39 and 40: estrogen receptor (MNAR), can activ
- Page 41 and 42: REFERENCES 1. Group EBCTC 1998 Tamo
- Page 43 and 44: 13. De Laurentiis M, Arpino G, Mass
- Page 45 and 46: 27. Klinge CM 2001 Estrogen recepto
- Page 47 and 48: 42. Schiff R, Massarweh S, Shou J,
- Page 49 and 50: antiestrogen-dependent membrane-ini
- Page 51 and 52: 70. Pedram A, Razandi M, Aitkenhead
- Page 53 and 54: 84. Bunone G, Briand PA, Miksicek R
- Page 55 and 56: antihormone response and prevents d
- Page 57 and 58: 110. Berry DA, Muss HB, Thor AD, Dr
- Page 59 and 60: of hormonal status and HER-2 in bre
- Page 61 and 62: 134. Daniel AR, Qiu M, Faivre EJ, O
- Page 63 and 64: 146. Baehner FL Quantitative RT-PCR
- Page 65 and 66: 158. Massarweh S, Shou J, DiPietro
- Page 67: 169. Polychronis A, Sinnett HD, Had
- Page 71 and 72: Figure 1 B Non-Classical Nuclear Ac
- Page 73: Figure 3 ER+PR+ ER+PR-
Change language